Table 3:
Outcomes and treatments of SARD patients over time
| Time period | ||||||
|---|---|---|---|---|---|---|
| Early COVID-19 | Early treatment | Early vaccination | Additional vaccination and Delta wave | Omicron wave | ||
| Overall (n = 1449) | March 1 2020 - June 30 2020 (n = 261) | July 1 2020 - Jan 31 2021 (n = 492) | Feb 1 2021 - June 30 2021 (n = 123) | July 1 2021 - Dec 16 2021 (n = 172) | Dec 17 2021 - Jan 31 2022 (n = 401) | |
| Hospitalization, n (%) | 391 (27.0%) | 115 (44.1%) | 142 (28.9%) | 40 (32.5%) | 36 (20.9%) | 58 (14.5%) |
| Mechanical ventilation, n (%) | 57 (3.9%) | 29 (11.1%) | 12 (2.4%) | 6 (4.9%) | 3 (1.7%) | 7 (1.7%) |
| Death, n (%) | 60 (4.1%) | 23 (8.8%) | 12 (2.4%) | 9 (7.3%) | 8 (4.7%) | 8 (2.0%) |
| Severe COVID-19* | 399 (27.5%) | 119 (45.6%) | 144 (29.3%) | 41 (33.3%) | 36 (20.9%) | 59 (14.7%) |
| Odds ratio | reference | 0.49 (0.36, 0.67) | 0.60 (0.38, 0.93) | 0.32 (0.20, 0.49) | 0.21 (0.14,0.30) | |
| Adjusted odds ratio† | reference | 0.58 (0.41, 0.81) | 0.89 (0.54, 1.46) | 0.39 (0.24, 0.62) | 0.29 (0.19, 0.43) | |
| Treatments Received, n (%) | ||||||
| Monoclonal antibodies‡ | 183 (12.6%) | 1 (0.4%) | 17 (3.5%) | 18 (14.6%) | 86 (50.0%) | 61 (15.2%) |
| Remdesivir | 206 (14.2%) | 18 (6.9%) | 90 (18.3%) | 29 (23.6%) | 21 (12.2%) | 48 (12.0%) |
| Convalescent plasma | 7 (0.5%) | 1 (0.4%) | 1 (0.2%) | 5 (4.1%) | 0 (0.0%) | 0 (0.0%) |
| Dexamethasone | 191 (13.2%) | 11 (4.2%) | 92 (18.7%) | 29 (23.6%) | 20 (11.6%) | 39 (9.7%) |
| Tocilizumab | 15 (1.0%) | 11 (4.2%) | 2 (0.4%) | 2 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Baricitinib | 3 (0.2%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.6%) | 2 (0.5%) |
Bolding indicated p<0.05. SARD, systemic autoimmune rheumatic disease; COVID-19, coronavirus disease 2019.
*
Composite outcome of hospitalization, mechanical ventilation, or death
†
Adjusted for age, sex, and race
‡
Includes bamlanivimab/etesevimab, casirivimab/imdevimab, and sotrovimab